Vosika G J, Ryan M J, Fortuny I A, Meyer C, Kiang D T, Theologides A, Kennedy B J
Med Pediatr Oncol. 1978;5(1):89-91. doi: 10.1002/mpo.2950050114.
Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.
晚期肾细胞癌对大多数经过充分评估的化疗药物相对耐药。在青蛙肾癌模型系统中具有抗肿瘤活性的环己亚硝脲（CCNU）和长春碱联合用药，在人体初步研究中已显示出活性。本研究调查了该药物组合与一种孕激素类药物己酸羟孕酮（Delalutin）联合使用的情况。17例转移性肾细胞癌患者接受了CCNU、长春碱和己酸羟孕酮治疗。未出现客观缓解。4例病情稳定的患者平均生存期为18个月，而13例病情进展的患者平均生存期为5个月。4例病情稳定患者的生存很大程度上归因于其疾病进展缓慢的自然病程。
